
Novartis/Sandoz Clear to Market Their Biosimilar Zarxio
Zarxio was approved earlier this month, the first biosimilar to be approved in the United States.
A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of
In his ruling, U.S. District Judge Richard Seeborg, of San Francisco federal court, denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once launched, would become the first approved biosimilar in the United States.
Link to the report on Reuters:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.